Nieder Carsten, Dalhaug Astrid, Haukland Ellinor, Mannsåker Bård, Pawinski Adam
a Department of Oncology and Palliative Medicine , Nordland Hospital , Bodø , Norway.
b Department of Clinical Medicine, Faculty of Health Sciences , UiT- The Arctic University of Norway , Tromsø , Norway.
Int J Circumpolar Health. 2017;76(1):1270080. doi: 10.1080/22423982.2016.1270080.
The aim of this study was to reduce barriers that prevent implementation of evidence-based recommendations about single-fraction palliative radiotherapy (PRT) and to demonstrate that single-fraction PRT yields similar outcomes as long-course treatment (≥10 fractions) in patients with bone metastases from breast cancer. This retrospective study (2007-2014) included 118 Norwegian female patients. All patients received guideline-conform systemic therapy including bone-targeting agents. Median survival was 12.7 months. Long-course PRT was prescribed in 60% of patients, while 21% had PRT with a single fraction of 8 Gy to at least one target. Reirradiation rate was not significantly higher after 8 Gy (9%, compared to 5% after long-course PRT and 6% after 4 Gy x5). Patients with favorable baseline characteristics such as younger age and good performance status (PS) were significantly more likely to receive long-course PRT. Biological subtype and comorbidity did not correlate with fractionation. Prognosis was influenced by biological subtype, extra-skeletal disease extent, severe anemia and abnormal CRP. The limited need for reirradiation after single fraction PRT might encourage physicians to prescribe this convenient regimen, which would improve resource utilization. Even patients with PS3 had a median survival of 3 months, which indicates that they could experience worthwhile clinical benefit.
本研究的目的是减少阻碍实施关于单次姑息性放射治疗(PRT)的循证建议的障碍,并证明在乳腺癌骨转移患者中,单次PRT与长疗程治疗(≥10次分割)产生相似的结果。这项回顾性研究(2007 - 2014年)纳入了118名挪威女性患者。所有患者均接受了符合指南的全身治疗,包括骨靶向药物。中位生存期为12.7个月。60%的患者接受了长疗程PRT,而21%的患者对至少一个靶区进行了单次8 Gy的PRT。8 Gy照射后的再照射率没有显著更高(9%,长疗程PRT后为5%,4 Gy×5后为6%)。具有如年龄较轻和良好体能状态(PS)等有利基线特征的患者显著更有可能接受长疗程PRT。生物学亚型和合并症与分割方式无关。预后受生物学亚型、骨骼外疾病范围、严重贫血和异常CRP的影响。单次PRT后对再照射的需求有限,这可能会促使医生采用这种便捷的治疗方案,从而提高资源利用效率。即使是PS3的患者中位生存期也有3个月,这表明他们可能会获得有价值的临床益处。